IASLC names Dr. Alex Adjei JTO Editor-in-Chief
IASLC names Dr. Alex A. Adjei JTO Editor-in-Chief
Adjei plans to expand on success of previous Editor, Dr. James Jett
DENVER – The International Association for the Study of Lung Cancer (IASLC) has named Alex A. Adjei, MD;PhD;FACP, the new Editor-in-Chief of the Journal of Thoracic Oncology (JTO). Dr Adjei, Professor and Chair of the Department of Medicine and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park Cancer Institute in Buffalo, New York, takes over January 1, 2013 from Dr. James Jett who has been the Editor of the journal since its launch in 2006.
Dr. Adjei has clear goals for the journal. “JTO should continue to be the premier source of authoritative and ground-breaking information in thoracic oncology,” he says. “The journal was ranked 50th out of all journals in oncology (185 journals ranked). A concerted effort to move JTO from an impact factor of 4.04 to above 7.0 in five years will place it in the top 20 of Oncology journals.”
Dr Adjei has extensive experience with scientific journals, and is a regular reviewer for more than 20 journals. He will step down from several of these to perform his new duties. He recently served as Senior Editor of Molecular Cancer Therapeutics, Section Editor for Medical Oncology of Cancer, Associate Editor of the American Journal of Clinical Oncology, Associate Editor of Current Drug Targets, and Section Editor-in-Chief of Frontiers in Pharmacology of Anticancer Drugs.
The Editor-in-Chief outlines some of the changes he will make to JTO in his opening Editorial in the January issue, where he also acknowledges his predecessor.
“I want to thank Dr. Jett for building a foundation and track record, which makes it easy and so interesting to expand on,” Adjei says. “I also want to thank the Board of Directors, Publication Committee, and the entire membership of IASLC for giving me the opportunity to grow this journal with them.”
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 3,500 lung cancer specialists in 80 countries. To learn more about IASLC please visit www.iaslc.org.